https://www.selleckchem.com/products/kpt-9274.html
HS patients had significantly higher hs-CRP levels than controls which decreased following treatment (p=0,010, p=0,007). No significant difference was found in serum levels of TNF-α, IL-1β, IL-17A, IL-23 compared to controls and post-treatment levels. There is insufficient data to suggest TNF-α, IL-1β, IL-17A and IL-23 as serum biomarkers in HS. hs-CRP can be used as an indicator of treatment response and systemic inflammation. There is insufficient data to suggest TNF-α, IL-1β, IL-17A and IL-23 as serum biomarkers in HS. hs-CRP can be
Like
Comment
Share
